# Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

> **NCT03621670** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1196 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)
- **BIOLOGICAL:** Prevnar13
- **BIOLOGICAL:** Pediarix
- **BIOLOGICAL:** Hiberix
- **BIOLOGICAL:** Rotarix
- **BIOLOGICAL:** M-M-R II
- **BIOLOGICAL:** Varivax
- **BIOLOGICAL:** Placebo (saline water)
- **BIOLOGICAL:** Prevnar 20

## Key facts

- **NCT ID:** NCT03621670
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-27
- **Primary completion:** 2024-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 1196 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03621670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03621670, "Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03621670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*